Hypermethylation and concurrent loss of TACSTD2 mRNA expression as a potential mark for epigenetic silencing has already been demonstrated for a number of human malignancies such as cholangiocarcinoma [35], lung adenocarcinoma [34], malignant glioma [43] and HCC [33]. The gene discussed is TACSTD2; the disease is lung adenocarcinoma.